Welcome to Womble Perspectives, where we explore a wide range of topics, from the latest legal updates to industry trends to the business of law. Our team of lawyers, professionals and occasional outside guests will take you through the most pressing issues facing businesses today and provide practical and actionable advice to help you navigate the ever changing legal landscape.
With a focus on innovation, collaboration and client service. We are committed to delivering exceptional value to our clients and to the communities we serve. And now our latest episode.
When we think about the human body, we often consider systems we learned about in biology class, like the central nervous system, the endocrine system, or maybe even the sympathetic nervous system. But today we’re shining a light on a crucial—but relatively new discovery in human physiology called the endocannabinoid system, or ECS for short.
Why pay attention to this system? Because understanding its role is essential to unlocking the therapeutic benefits of cannabis.
But first things first, what is the endocannabinoid system?
The ECS is a biological system we all have, whether we’ve used cannabis or not. It plays a massive role in regulating core processes in our body—from mood and sleep to appetite, memory, and even pain. It’s like the body’s backstage crew, quietly keeping everything running smoothly.
The ECS has three main components:
First, endocannabinoids. These are naturally occurring compounds produced by your body. Think of them as messengers that communicate with other systems to maintain balance.
Second, cannabinoid receptors. Found throughout the body, these receptors are like little locks waiting for the right keys. When endocannabinoids (or cannabis compounds like THC and CBD) bind to them, they unlock specific changes.
And third, enzymes. These are responsible for creating and breaking down endocannabinoids when they’re no longer needed.
The ECS interacts with compounds found in cannabis. THC, for example, binds directly to these receptors to produce its psychoactive effects. CBD, on the other hand, works differently by influencing how the receptors respond, offering therapeutic benefits without the “high.”
And speaking of therapeutic benefits, current research is shining a spotlight on how the ECS can be harnessed for medical treatment. Let's take a closer look.
One area where understanding the ECS offers tremendous promise is pediatric diseases. For instance, cannabis-based medical products are being studied for conditions like childhood cancer, treatment-resistant epilepsy, and even rare congenital disorders like Sturge-Weber Syndrome, or SWS.
SWS is a rare condition that presents with a facial birthmark, brain vessel abnormalities, and neurological issues like epilepsy.
Enter Epidiolex, an oral solution approved by the FDA in 2018 for some severe forms of epilepsy. Recent studies show it might also benefit SWS patients by reducing seizures, improving cognitive function, and enhancing overall quality of life.
For parents who’ve been told there are no more treatment options, this emerging research could change the narrative.
Moving on to another arena of research, we’ve also seen cannabis being used in the treatment of pediatric cancer symptoms.
When traditional treatments fail to manage pain, nausea, and vomiting, cannabinoids step in as a promising alternative by binding to ECS receptors and blocking the release of neurotransmitters that cause nausea.
What’s even more encouraging is this finding: across numerous studies, no serious adverse effects have been linked to cannabis use in children. That said, researchers caution that more work needs to be done to determine ideal dosages.
Now, let's turn to the future and what it might hold for the ECS and cannabis research.
The endocannabinoid system is far from fully understood. What we do know is that it holds incredible potential for developing treatments across a broad spectrum of conditions—not just for children but also for adults.
Ongoing studies are examining how ECS-targeted therapies might support patients with chronic pain, mental health disorders, or even autoimmune diseases. If this turns out to be the case cannabinoids could become a first line of defense for managing conditions traditionally treated with invasive procedures or harsh pharmaceuticals.
And as researchers continue to study the ECS, there’s hope that we’ll unlock more complex interactions and applications for cannabis-based medicines.
To sum it all up, the endocannabinoid system is one of the body’s most fascinating regulatory networks, and it’s paving the way for breakthroughs in therapeutic cannabis research. From epilepsy and pediatric cancer to its potential for adult treatments, the ECS is proving to be a vital target for improving global health outcomes.
Thank you for listening to Womble Perspectives. If you want to learn more about the topics discussed in this episode, please visit The Show Notes, where you can find links to related resources mentioned today. The Show Notes also have more information about our attorneys who provided today's insights, including ways to reach out to them.
Don't forget to subscribe via your podcast player of choice so that you never miss an episode. Thank you again for listening.
